Showing 641-650 of 7665 results for "".
- St. Ives Launches Social Media Contest to Help Reduce College Students' Financial and Skin Stresshttps://practicaldermatology.com/news/st-ives-launches-social-media-contest-to-help-reduce-college-students-financial-and-skin-stress/2460961/St. Ives –with its new Solutions product line –aims to give one lucky student even less to stress about, offering the opportunity to win up to $50,000 for free tuition and books for one year as well as a year's worth of St. Ives Solutions for glowing skin. With the help of actress and recent colle…
- Study: Laser Plus Topical Steroids May Improve VLS Symptomshttps://practicaldermatology.com/news/study-laser-plus-topical-steroids-may-improve-vls-symptoms/2460959/Adding fractional CO2 laser treatments to topical steroids may maximize treatment outcomes in refractory vulvar lichen sclerosus (VLS), according to a new study in Lasers in Surgery and Medicine. “VLS is a relatively common condition that, unfortunately, is often under-recognized and under-treated…
- Link Between Melanoma and Estrogen May Lead to New Therapeutic Approachhttps://practicaldermatology.com/news/link-between-melanoma-and-estrogen-may-lead-to-new-therapeutic-approach/2460953/The link between estrogens and breast cancer has long been defined, but a Duke-led research team has identified how these hormones can also influence the growth of other cancers, notably melanoma. Building on observations that male melanoma patients wh…
- Reistone’s Topical JAK Inhibitor Performs Well in Mild to Moderate ADhttps://practicaldermatology.com/news/reistones-topical-jak-inhibitor-performs-well-in-mild-to-moderate-ad/2460951/Reistone Biopharma’s SHR0302 ointment performed well in a Phase 2 study of patients with mild-to-moderate atopic dermatitis (AD), the company reports. SHR0302 ointment, a topical, selective JAK1 inhibitor, met key primary and secondary endpoints, demonstrating significant improvement in percent ch…
- Proscia's AI Technology Accurately Identifies Melanomas in Prospective Studyhttps://practicaldermatology.com/news/proscias-ai-technology-accurately-identifies-melanomas-in-prospective-study/2460944/Results of a prospective study just released demonstrate that an artificial intelligence (AI) technology solution from Proscia can automatically detect melanoma with a high degree of accuracy. Conducted at Thomas Jefferson University in Philadelphia and the University of Florida, the study assesse…
- It's Eczema Awareness Monthhttps://practicaldermatology.com/news/its-eczema-awareness-month/2460932/Recognizing that the daily impact and overall burden of eczema for each individual can differ greatly from person to person and within a person's lifetime, the National Eczema Association (NEA) is highlighting various aspects of the disease during Eczema Awareness Month in October. NEA has launche…
- Castle Creek, Mayo Clinic to Collaborate on Therapies for Rare Genetic Connective Tissue Disordershttps://practicaldermatology.com/news/castle-creek-mayo-clinic-to-collaborate-on-therapies-for-rare-genetic-connective-tissue-disorders/2460930/Castle Creek Biosciences, Inc. is collaborating with Mayo Clinic to advance discovery and pre-clinical development of investigational gene therapy candidates for the treatment of osteogenesis imperfecta (OI) and classical Ehlers-Danlos syndrome (EDS). Neither rare genetic connective tissue disorder…
- Nutrafol May Promote Hair Growth in Menopausal Womenhttps://practicaldermatology.com/news/nutrafol-may-promote-hair-growth-in-menopausal-women/2460923/Nutrafol may improve hair growth and quality for perimenopausal, menopausal, and postmenopausal women, according to research presented during The North American Menopause Society (NAMS) Annual Meeting in Washington, DC. Researchers compared results at 6 months and 12 months of treatment and found…
- Mayne Pharma's Lexette Approved for Adolescentshttps://practicaldermatology.com/news/mayne-pharmas-lexette-approved-for-adolescents/2460921/Lexette® (halobetasol propionate) foam, 0.05% from Mayne Pharma is now approved for the treatment of plaque psoriasis in patients aged 12 years and older. FDA approved Lexette in 2018 for use in adults. Approval in adolescents is based on data obtained in an open label follow-on study to the init…
- Dermala Scores New Patent Covering the Use of Human Microbiome to Prevent, Slow, and Reverse Skin Aginghttps://practicaldermatology.com/news/dermala-scores-new-patent-covering-the-use-of-human-microbiome-to-prevent-slow-and-reverse-skin-aging/2460910/Dermala has received issuance of a U.S. Patent to use the human microbiome to slow down the skin aging process. The newly patented technology uses novel microbiome formulations and delivery methods to restore biologically "younger" skin and gut microbiomes in older adults. This includes transplan…